• iconOpp IPH Colony Tira Road Sujanpur H.P.
  • icondivyanshpanchkarma@gmail.com

Opening Hours : Monday to Saturday - 10 AM to 5 PM


Need Help? call us.

70180 11501, 70185 26626, 01972 295677

Renalsense Announces Distribution Agreement in Israel with Medtechnica

Renalsense Announces Distribution Agreement in Israel with Medtechnica

RenalSense, a leading medical device company specializing in renal care technology, has recently announced its distribution agreement with Medtechnica, a prominent Israeli medical device distributor. This partnership is geared towards providing high-quality renal care technology to healthcare providers and patients in Israel.

This partnership is expected to significantly impact Israel`s renal care industry, as both companies are renowned for their expertise in the field. RenalSense`s Clarity RMS System, which is a real-time monitoring system that helps clinicians manage fluid status and prevent acute kidney injury (AKI) in critical care patients, will be a major focus of this partnership. The system provides continuous measurements of urine flow, urine temperature, and core body temperature, and delivers them to a monitor, enabling clinicians to identify and mitigate AKI risk factors effectively.

Medtechnica`s extensive distribution network in Israel will provide RenalSense with an avenue to make its technology more accessible to healthcare providers and patients in the region. The company has a reputation for delivering quality medical devices to the Israeli market, and this partnership is expected to bolster its offerings in the renal care technology space.

The Clarity RMS System is already being used in over 50 hospitals worldwide, and its efficacy in preventing AKI has been widely proven. The system is easy to use and has shown to reduce healthcare costs by decreasing the length of hospital stays, improving patient outcomes, and reducing the need for costly interventions.

The partnership between RenalSense and Medtechnica is expected to have positive implications for patients in Israel who need renal care, as clinicians will have access to an innovative technology that enhances their ability to manage and prevent AKI effectively. Additionally, healthcare providers will benefit from the reduction in healthcare costs and improvement in patient outcomes associated with the use of the Clarity RMS System.

In conclusion, RenalSense`s partnership with Medtechnica represents a significant milestone for the renal care industry in Israel. This collaboration between two leading companies in the field is expected to promote better patient outcomes, reduce healthcare costs, and provide greater access to renal care technology in the region. It is a win-win situation for all stakeholders involved, and the hope is that this alliance will inspire further innovation in the renal care industry.